Literature DB >> 34647827

Positive expiratory pressure: a potential therapy to mitigate acute bronchoconstriction in the asthma of obesity.

Swati A Bhatawadekar1, Anne E Dixon1, Ubong Peters1, Nirav Daphtary1, Kevin Hodgdon1, David A Kaminsky1, Jason H T Bates1.   

Abstract

Late-onset nonallergic (LONA) asthma in obesity is characterized by increased peripheral airway closure secondary to abnormally collapsible airways. We hypothesized that positive expiratory pressure (PEP) would mitigate the tendency to airway closure during bronchoconstriction, potentially serving as rescue therapy for LONA asthma of obesity. The PC20 [provocative concentration of methacholine causing 20% drop in forced expiratory volume in 1 s (FEV1)] dose of methacholine was determined in 18 obese participants with LONA asthma. At each of four subsequent visits, we used oscillometry to measure input respiratory impedance (Zrs) over 8 min; participants received their PC20 concentration of methacholine aerosol during the first 4.5 min. PEP combinations of either 0 or 10 cmH2O either during and/or after the methacholine delivery were applied, randomized between visits. Parameters characterizing respiratory system mechanics were extracted from the Zrs spectra. In 18 patients with LONA asthma [14 females, body mass index (BMI): 39.6 ± 3.4 kg/m2], 10 cmH2O PEP during methacholine reduced elevations in the central airway resistance, peripheral airway resistance, and elastance, and breathing frequency was also reduced. During the 3.5 min following methacholine delivery, PEP of 10 cmH2O reduced Ax and peripheral elastance compared with no PEP. PEP mitigates the onset of airway narrowing brought on by methacholine challenge and airway closure once it is established. PEP thus might serve as a nonpharmacological therapy to manage acute airway narrowing for obese LONA asthma.NEW & NOTEWORTHY Standard pharmacological treatments are not effective in people with obesity and asthma. We assessed the efficacy of positive expiratory pressure (PEP) as a therapy to mitigate airway hyperresponsiveness in the asthma of obesity. Our results indicate that PEP might serve as a nonpharmacological therapy to manage acute airway narrowing in obese individuals with late-onset nonallergic asthma.

Entities:  

Keywords:  late-onset nonallergic asthma; lung volume; obese asthma; obesity; positive expiratory pressure

Mesh:

Substances:

Year:  2021        PMID: 34647827      PMCID: PMC8714981          DOI: 10.1152/japplphysiol.00399.2021

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  29 in total

1.  Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.

Authors:  R O Crapo; R Casaburi; A L Coates; P L Enright; J L Hankinson; C G Irvin; N R MacIntyre; R T McKay; J S Wanger; S D Anderson; D W Cockcroft; J E Fish; P J Sterk
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

2.  Respiratory function tests; normal values at median altitudes and the prediction of normal results.

Authors:  H I GOLDMAN; M R BECKLAKE
Journal:  Am Rev Tuberc       Date:  1959-04

Review 3.  Standardisation of the measurement of lung volumes.

Authors:  J Wanger; J L Clausen; A Coates; O F Pedersen; V Brusasco; F Burgos; R Casaburi; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D Johnson; N Macintyre; R McKay; M R Miller; D Navajas; R Pellegrino; G Viegi
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

4.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

5.  Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.

Authors:  Meghan E McGarry; Elizabeth Castellanos; Neeta Thakur; Sam S Oh; Celeste Eng; Adam Davis; Kelley Meade; Michael A LeNoir; Pedro C Avila; Harold J Farber; Denise Serebrisky; Emerita Brigino-Buenaventura; William Rodriguez-Cintron; Rajesh Kumar; Kirsten Bibbins-Domingo; Shannon M Thyne; Saunak Sen; Jose R Rodriguez-Santana; Luisa N Borrell; Esteban G Burchard
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

6.  Influence of body mass index on the response to asthma controller agents.

Authors:  M Peters-Golden; A Swern; S S Bird; C M Hustad; E Grant; J M Edelman
Journal:  Eur Respir J       Date:  2006-03       Impact factor: 16.671

7.  Does body mass index influence responsiveness to inhaled corticosteroids in persistent asthma?

Authors:  William J Anderson; Brian J Lipworth
Journal:  Ann Allergy Asthma Immunol       Date:  2012-01-21       Impact factor: 6.347

8.  Airway inhomogeneities contribute to apparent lung tissue mechanics during constriction.

Authors:  K R Lutchen; Z Hantos; F Peták; A Adamicza; B Suki
Journal:  J Appl Physiol (1985)       Date:  1996-05

9.  Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation.

Authors:  Anne E Dixon; Richard E Pratley; Patrick M Forgione; David A Kaminsky; Laurie A Whittaker-Leclair; Laurianne A Griffes; Jayanthi Garudathri; Danielle Raymond; Mathew E Poynter; Janice Y Bunn; Charles G Irvin
Journal:  J Allergy Clin Immunol       Date:  2011-07-23       Impact factor: 10.793

10.  Obesity and asthma: an inflammatory disease of adipose tissue not the airway.

Authors:  Olga Sideleva; Benjamin T Suratt; Kendall E Black; William G Tharp; Richard E Pratley; Patrick Forgione; Oliver Dienz; Charles G Irvin; Anne E Dixon
Journal:  Am J Respir Crit Care Med       Date:  2012-07-26       Impact factor: 21.405

View more
  1 in total

Review 1.  Understanding the fundamentals of oscillometry from a strip of lung tissue.

Authors:  Ynuk Bossé
Journal:  Front Physiol       Date:  2022-09-20       Impact factor: 4.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.